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Background: Adenosylcobalamin (vitamin B12) is a coenzyme required for the activity
of methylmalonyl-CoA mutase. Defects in this enzyme are a cause of methylmalonic
acidemia (MMA). Methylmalonic acidemia, cblA type, is an inborn error of vitamin B12
metabolism that occurs due to mutations in the MMAA gene. MMAA encodes the
enzyme which is involved in translocation of cobalamin into the mitochondria.
Methods: One family with two MMA-affected children, one unaffected child, and their
parents were studied. The two affected children were diagnosed by urine organic acid
analysis using gas chromatography-mass spectrometry. MMAA was analyzed by PCR
and sequencing of its coding region.
Results: A homozygous deletion in exon 4 of MMAA, c.674delA, was found in both
affected children. This deletion causes a nucleotide frame shift resulting in a change from
asparagine to methionine at amino acid 225 (p.N225M) and a truncated protein which
loses the ArgK conserved domain site. mRNA expression analysis of MMAA confirmed
these results.
Conclusion: We demonstrate that the deletion in exon 4 of the MMAA gene (c.674
delA) is a pathogenic allele via a nucleotide frame shift resulting in a stop codon and
termination of protein synthesis 38 nucleotides (12 amino acids) downstream of the
deletion.
Keywords: Mutation analysis, MMAA gene, Biochemical analysis, Methylmalonic
acidemia, Vitamin B12, Novel deletion, Cobalamin, Structural analysis
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Vitamin B12, also called cobalamin (Cbl), is a water-soluble vitamin with an important
role in brain and nervous system function. It is involved in the metabolism of fatty and
amino acids and is an essential vitamin that must be provided in the diet [1]. Inborn
errors of cobalamin metabolism cause dysfunction in two essential coenzymes,© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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tivity of the mitochondrial enzyme methylmalonyl-CoA mutase (MCM, EC 5.3.99.2),
which catalyzes the conversion of methylmalonyl-CoA to succinyl-CoA during catabol-
ism of branched-chain amino acids and odd-chain fatty acids. Disorders that impair
synthesis of AdoCbl cause accumulation of methylmalonic acid in urine and blood due
to decreased activity of methylmalonyl-CoA mutase, which leads to methylmalonic
acidemia (MMA) [2].
Individuals affected with this disorder present with lethargy, failure to thrive, recurrent
vomiting, dehydration, respiratory distress, and hypotonia in the first year of life [2].
The gene responsible for cblA has been identified as MMAA [3]. MMAA is located
on chromosome 4q31.1–2, and consists of seven exons that encode a protein contain-
ing 418 amino acids. Two different enzymatic functions have been identified for the
MMAA gene product: a role in vitamin B12 transport into the mitochondria, and the
conservation or re-activation of MCM [4]. In this study, we report the clinical, bio-
chemical, and genetic defects and structural analysis of MMAA in one Iranian family
with isolated MMA.We demonstrate that this novel deletion in exon 4 of MMAA is a
pathogenic allele that results in a premature stop codon and subsequent truncated pro-
tein and the loss of the important binding sites of the protein due to loss of the ArgK
(PF03308) conserved domain.Materials and methods
Patients and MMA diagnosis
One family with two MMA-affected children, one unaffected child, and their parents
were studied. A daughter who died five days after birth was not assessed. The two af-
fected children were diagnosed after presenting with clinical symptoms and high levels
of methylmalonic acid by urine organic acid analysis. All procedures followed were in
accordance with the ethical standards of the committee on human experimentation of
MUMS (Mashhad University of Medical Science). Informed consent was obtained from
all subjects for being included in the study.Mutation and mRNA expression analysis
DNA was extracted from the family members’ blood samples using the salting-out
method [5]. MMAA exon 4 and flanking sequences were amplified by PCR using primers
designed with Beacon Designer (forward: 5′-AGGAACTGGCTGATAATTGA-3′, re-
verse: 5′-AGGGAGTATGGGATATCTTG-3′). For expression analysis, RNA was isolated
using Trizol reagent (Invitrogen). RT-PCR was performed and the coding sequence was
amplified using primers designed with Beacon Designer (forward: 5′-TACCACAGAGAA-
CAAGAACAATCA-3′, reverse: 5′-GCACAATCAAGTCTCCATCAG-3′). At least two
PCR products were directly sequenced and products of the sequencing reaction were ana-
lyzed using DNA Sequencher 4.7.Structural and functional analysis
The novel mutation (p.N225M) was considered for the purpose of structural modeling
in order to completely understand the vast structural damages caused by truncation of
the protein after the occurrence of the deduced novel mutation in comparison with the
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modeling would help to better understand the vast dysfunctioning of the mutated pro-
tein by visually analyzing it. To accomplish it, the template most similar to the deduced
normal protein with 95.7 % sequence similarity (Swiss Model Template ID (SMTL ID):
2www.1) was chosen and used to build the tertiary structure of the normal and mu-
tated proteins by using the online Swiss-Prot server for automated modeling [6]. The
2www.1 structure has been solved to 2.64 Å using the X-ray diffraction method [7].
The structures were then considered for the purpose of the energy minimization task
using ZMM software. ZMM software uses amber-all-atom force field with the cut-off
distance of 10 Å to minimize the conformational energy in the space of generalized co-
ordinates [8]. Low energy conformation was reached after 100 sequential tasks of en-
ergy minimization failed to actually enhance the quality of the assembled structures [9].
The resulting models were finally analyzed in terms of essential accuracy aspects such
as G-Factor, bond length and bond angles by the help of PROCHECK [10] and WHAT-IF
[11] online programs for of which all the results satisfied the important criteria. Moreover,
most of the residues were inside of the favorable regions of the Ramachandran map.
In addition to revealing the structural defects, the effects of this novel mutation
(p.N225M) on the function of the deduced protein was further investigated by consid-
ering its mutational role on the function of the conserved ArgK (PF03308) domain
which starts at LUE p.101 and ends at THR p.384.Results and discussion
Clinical symptoms and biochemical findings
This novel deletion was identified in two children: a 4-year-old girl with metabolic
problems, and her 1.5-year-old brother. Both children had signs and symptoms of
MMA. The family pedigree is shown in Fig. 1a. The clinical symptoms and biochemical
findings of the two affected children are presented below:
The girl, who was a product of a consanguineous marriage, was born at term follow-
ing a normal pregnancy. She was admitted to the hospital at 2 months of age with a
history of persistent vomiting and progressive lethargy. Pyruvate was 1.49 mg/dL (nor-
mal, 0.3–0.7), ammonia was 197.60 mmol/L (normal, 64–107), lactate was 42.1 mg/dL
(normal, 0 to 20), venous pH was 7.48 (normal, 7.35–7.45), and bicarbonate was 21.9
mmol/L (normal, 22–28). Tandem mass spectrometry analysis showed significant eleva-
tion of propionylcarnitine (13 μmol/L), which may be indicative of MMA or propionic
acidemia (PA). Urine organic acid analysis indicated abnormally high excretion of
methylmalonic acids (1250 mmol/mol creatinine). She was diagnosed with MMA and
treated with protein restriction, daily intramuscular hydroxycobalamin injections (1.0
mg), Shohl’s solution (4.5 ml/day), benzoate tablets (250 mg/day), L-carnitine (5 ml/
day), and metronidazole syrup (4.5 ml/day). At 4 months she presented with lethargy,
vomiting, hepatomegaly, hypotonia, anorexia, developmental delay, and failure to
thrive. At 10 months she had begun to achieve sufficient weight and showed develop-
mental and hypotonia improvement with protein restriction and L-carnitine and hydro-
xycobalamin injections. In the third year of treatment, her urinary methylmalonic acid
excretion was 12 mmol/mol creatinine, but development and movement were delayed
compared with normal individuals.
Fig. 1 Family pedigree and DNA sequence chromatograms of family members (a) Family pedigree and
mutation analysis for exon 4 of MMAA (b) A DNA sequence chromatogram of the family members (B1) DNA
sequence chromatogram of the affected daughter (4 years old) with the homozygous c.674delA mutation (B2)
DNA sequence chromatogram of the affected son (1.5 years old) with the homozygous c.674delA mutation (B3)
DNA sequence chromatogram of the father with the heterozygous c.674delA mutation (B4) DNA sequence
chromatogram of the mother with the heterozygous c.674delA mutation (B5) DNA sequence chromatogram of
the unaffected son with the heterozygous c.674delA mutation
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no symptoms of MMA were observed. He was hospitalized at 1.5 years of age for
persistent vomiting and infection. Glucose was 250 mg/dL (normal, 70–105), ven-
ous pH was 7.07 (normal, 7.35–7.45), bicarbonate was 6.5 mmol/L (normal, 22–
28), blood urea was 55 mg/dL, and creatinine was 0.5 mg/dL. He was treated for
MMA with L-carnitine, sodium benzoate, and vitamin B12. Dialysis was initiated,
but he died on the second day of hospitalization.Novel MMAA deletion and mRNA expression analysis
The family pedigree and sequence chromatograms for exon 4 of MMAA from the
five family members are shown in Fig. 1. A homozygous deletion in exon 4 of
MMAA, c.674delA, was found in both the affected son and daughter. An adenine
deletion was detected at position c.674 in exon 4. This deletion predicted a nucleo-
tide frame shift and amino acid change from asparagine to methionine at position
225 (p.N225M), resulting in a premature TAA stop codon at position 238 and
truncation of the protein 12 amino acids downstream of the methionine produced
by the frame shift. We confirmed the mutation’s homozygosity through analyses of
the parents’ and unaffected son’s samples. We found one heterozygous variant in
exon 4 of MMAA, c.674delA. This mutation has been recorded in the GenBank
database with accession number KR026958. These results, from two affected and
one unaffected siblings and their parents, confirmed the diagnosis of cblA-deficient
MMA. MMAA mRNA expression analysis identified the expected truncated mes-
sage. The mRNA expression analysis and sequencing chromatogram of expression
analysis are shown in Fig. 2. The premature TAA stop codon 12 amino acids
downstream of the methionine produced by the frame shift are shown in this
figure.
Fig. 2 cDNA sequence chromatogram and expression analysis of β-actin and MMAA gene. a cDNA sequence
chromatogram of MMAA from the affected daughter and the corresponding amino acid sequence, premature
TAA stop codon 12 amino acids downstream of the methionine produced by the frame shift (green) (b) β-actin
(size: 113 bp): Lanes 1: 100 bp marker, 2: cDNA from the affected daughter with the c.674delA mutation, 3:
cDNA from a normal control, 4: negative control. c MMAA, exon 4, size: 508 bp):Lanes 1: 1 kbp marker, 2: cDNA
from the affected daughter with the c.674delA mutation, 3: cDNA from a normal control, 4: negative control
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As discussed above and shown in Fig. 3, the novel mutation (p.N225M) is the
underlying cause of a big frame shift and the loss of a large part of the deduced
novel protein due to the early truncation which results in conformational instabil-
ity. The modeling of the deduced novel mutation also reveals the structural im-
portance of the cutting regions in dysfunctioning of the MMAA novel mutated
protein. The MMAA protein contains the ArgK (PF03308) conserved domain
which starts at p.101 and ends at p.384. Therefore a very large part of the protein
lost (from p.225 to the end) contains the elements of this conserved domain site.
The function of this domain is not completely known yet. However, it may have
GTPase and ATPase activity and may also contain important binding sites of the
MMAA protein due to its roles and conservation history. Moreover, the MMAA
protein is a cobalamin cofactor which is considered to have a confident (vastly re-
ported in the literature: data collected from www.string-db.org at String:
9606.ENSP00000281317) interaction with MUT protein. The MUT gene has a B12-
binding site which can bind two different types of cobalamin cofactors, methylco-
balamin and adenosylcobalamin, like the one described here [12–14]. It can thus
be assumed that the loss of a large part of the MMAA protein (involving the con-
served domain ArgK (PF03308) due to the novel mutation p.N225M) and the alter-
ation of twelve amino acids (LYS p.226 to THR p.237) which happened due to the
frame shift caused by c.674delA may drastically affect the binding activity of these
two proteins. This effect can be considered as either removing the complete inter-
action sites or reducing the binding parts between them in such a way that the
resulting proteins may fail to interact completely. Therefore in both situations the
resulting interaction would not be completely functional.
Fig. 3 Whole view of the normal protein MMAA by the use of 2www structure (above left); close view of
the normal protein MMAA (above right); whole view of the novel mutated MMAA protein (p.N225M) by the
use of 2www structure (below left); close view of the novel mutated protein MMAA (below right). Red circles
in pictures show low complexity regions
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In 1968, Rosenberg and Lindblad described infants with severe metabolic ketoaci-
dosis and developmental delay with abnormally high levels of methylmalonate in
their blood and urine. Treatment of these infants with AdoCbl reduced both the
severity of their symptoms and methylmalonate excretion [15, 16]. Further studies
indicated that these infants expressed normal methylmalonyl CoA mutase, but syn-
thesis of AdoCbl was impaired [17, 18]. Kaye et al. (1974), reported two patients
with MMA who expressed normal methylmalonyl CoA mutase, but were defective
in AdoCbl synthesis and unresponsive to cyanocobalamin treatment. Biochemical
and genetic analyses showed that cblB was also defective in these patients [19].
Since then, more than 45 different disease-causing mutations have been identified
in MMAA, which include 30 missense or nonsense mutations, four splicing muta-
tions, five small deletions, five small insertions, and one gross deletion. All the mu-
tations are available on the Human Gene Mutation Database (HGMD) [20–24]. It
is also very interesting to know that the MMAA protein has a low complexity re-
gion which starts at p.213 and ends at p.224, an amino acid before the reported
novel mutation (p.N225M). Low complexity regions are prone to mutation as de-
scribed previously [25] and in our case; the mutation occurred immediately after
the end of this region. This low complexity region is demonstrated in both normal
and novel mutated (p.N225M) MMAA protein in Fig. 3 above. Molecular analysis
has not been performed on MMAA in the Iranian population. Early detection of
MMA is critical; the girl in this family who was diagnosed at 2 months has sur-
vived, while the boy, who was diagnosed at 1.5 years, died soon after. Early diagno-
sis can prevent metabolic crises and mental retardation. Identification of mutations
in MMA patients aids prenatal diagnoses and determination of the parents’ and
relatives’ carrier status.
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